



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 24 July 2023 (#27)

Confirm your intent to apply **ASAP**, but not later than **60 days** before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

To prepare an application can take **4-18 months**, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

Before starting your application, attend the **1) Generic Grant Writing Workshop** and then the **2) NIH Grant Writing Workshop**.

Important Notices

Fogarty-leDEA Mentorship Program (FIMP): Current and former Fogarty D43 trainees and leDEA-affiliated regional investigators develop skills in study design, data management, analysis, interpretation, and dissemination of research involving large HIV clinical databases generated within leDEA. **Application deadline:** October 23, 2023.

Informational webinars:

- Tuesday, August 1 at 9 pm ET/USA
- Thursday, August 3 at 9 am ET/USA
- Friday, August 4 at 9 am ET/USA

Application portal: Apply online, get webinar information and answers to frequently asked questions

NOT-HD-23-020 Notice NICHD Participation on PAR-23-190: "Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, treatment and Care in Low- and Middle-Income Countries (R01 - Clinical Trial Optional). The purpose of this notice is to inform potential applicants that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will participate, effective immediately, in PAR-23-190, "Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R01-Clinical Trial Optional)".

Parent Announcements

NOT-OD-23-105 Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities. Current Key Dates *Expiration Date: May 8, 2023* **Modified Key Dates** *Expiration Date: May 8, 2024*

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- **PA-20-185** NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- **PA-20-184** Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- **PA-20-183** Research Project Grant (Parent R01 Clinical Trial Required)
- **PA-20-200** NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- **PA-20-195** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- **PA-20-194** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- **PA-20-196** NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest

[NOT-AI-23-044](#) Administrative Supplement for Collaborative Projects Supported by the NIAID/RNCP. The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID's interest in supporting research aimed at fostering collaborations between researchers throughout the NIAID/Radiation and Nuclear Countermeasures Program (RNCP)-funded grant and cooperative agreement portfolio (e.g., U01, U19, R21, R01, P01). The NIAID/RNCP has been tasked with developing safe and effective medical countermeasures (MCMs) and biodosimetry tools for civilians that can be used at least 24 hours post-exposure in a radiological or nuclear public health emergency. The multidisciplinary nature of radiation research lends itself to the establishment of formal partnerships across projects with similar goals, which enables collaborating research groups to achieve outcomes that would likely be impossible without the expertise, models, and facilities available at other institutions. The goal of NOSI is to foster collaborations that will allow awardees to develop data that can be leveraged for new funding that will enhance the state-of-the-science.

[NOT-MH-23-200](#) Innovative Technologies to develop novel tools to prevent and treat HIV in underserved populations. Emerging digital health technologies in HIV research is a growing and dynamic field that has the potential to bring HIV prevention and treatment efforts to scale. Innovations in technology can assist in reaching high-incidence populations, such as racial or ethnic minority communities, sexual and gender minority groups, adolescents and young adults, and individuals from rural settings who face challenges in accessing conventional prevention and treatment services. The aim of this Notice of Special Interest (NOSI) is to support the development of new technologies for the prevention or treatment of HIV, or the application of existing technologies to behavioral and social science HIV prevention or treatment research.

Notice of Funding Opportunity (NOFO)

1. Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-23-238](#)

Type: R01

Application Due Date: October 05, 2023 through to July 05, 2026. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The purpose of this Notice of Funding Opportunity (NOFO) is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. This NOFO solicits R01 applications, while the companion announcement [PAR-23-239](#) solicits R21 applications. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Health Equity and the Cost of Novel Treatments for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R61/R33 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-24-050](#)

Type: R61/R33

Application Due Date: October 31, 2023 Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: This notice of funding opportunity (NOFO) invites applications to address health equity, drug costs, and access to new therapeutics for people living with Alzheimer's disease (AD) and AD-related dementias (ADRD). Applicants must identify preferences for pharmacological treatment among racial and ethnic minorities living with AD/ADRD, assess whether cost barriers to pharmacological care exist for these groups, and quantify expenditures and health-related quality of life (HRQoL) among people interested in receiving novel drugs to treat AD/ADRD. This NOFO utilizes the [R61/R33](#) Exploratory/Developmental Phased Award activity code. The R61 phase supports research to conduct rigorous stakeholder engagement with people from racial and ethnic minority groups to identify, measure, and assess the demand for new drugs. The R33 phase supports rigorous research modeling of health-related costs and HRQoL and the dissemination of model findings. At the completion of the R61 phase, grantees must submit a detailed request to transition to the R33 phase.

Budget: NIA intends to commit \$1.2 million in FY 2024 to fund 4 awards. For the R61 phase, the budget for direct costs may not exceed \$200,000 per year. For the R33 phase, the budget for direct costs may not exceed \$400,000 per year. Application budgets need to reflect the actual needs of the proposed project. The maximum period of the combined R61/R33 phases is 5 years, with 1-2 years for the R61 phase and 3-4 years for the R33 phase. Funding of the R33 award will be determined by successful completion of the R61 milestones, program priorities, and availability of funds, as determined by NIH.

3. HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-24-063](#)

Type: R01

Application Due Date: February 01, 2024. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The purpose of this notice of funding opportunity (NOFO) is to support research focusing on the identification of druggable new targets and the discovery of optimizable probes for the development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. This NOFO is part of the NIH Helping to End Addiction Long-term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose. For information about Novel Therapeutic Options for Opioid Use Disorder and Overdose, see <https://heal.nih.gov/research/medication-options>. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available [PEDP guidance material](#).

Budget: The NIH HEAL (Helping to End Addiction Long-term) Initiative intends to commit an estimated total of \$5 million to fund 8-10 awards in response to this and the companion notice of funding opportunity in FY 2024. Awards pursuant to this funding opportunity are contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to \$400,000 in direct costs per year and need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

4. HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-24-064](#)

Type: R21

Application Due Date: February 01, 2024. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The purpose of this notice of funding opportunity (NOFO) is to support research focusing on the identification of druggable new targets and the discovery of optimizable probes for the development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. This NOFO is part of the NIH Helping to End Addiction Long-term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose. For information about Novel Therapeutic Options for Opioid Use Disorder and Overdose, see <https://heal.nih.gov/research/medication-options>. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available [PEDP guidance material](#).

Budget: The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is 2 years.

5. Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-25-014](#)

Type: R61/R33

Application Due Date: August 21, 2024; August 14, 2025. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The purpose of this notice of funding opportunity (NOFO) is to seek applications that examine protein interaction networks in HIV-infected microglia, and how these host-viral interactions contribute to cell type- and brain region-specific alterations in cellular signaling in the context of comorbid HIV and substance use disorder (SUD).

Budget: NIDA intends to commit \$2.5M in FY 2025 to fund 3-6 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. Projects proposed may not exceed five years of total effort.

6. Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-25-019](#)
[RFA-DA-25-020](#)

Type: R01
R34

Application Due Date: August 20, 2024; March 19, 2025. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The purpose of this notice of funding opportunity (NOFO) is to support the testing of enhanced models of care that optimally integrate HIV and Hepatitis B and C, addiction, and primary care services. The National Institute on Drug Abuse (NIDA) is interested in research that addresses gaps related to the delivery of comprehensive, integrated health services to include the full continuum of HIV/AIDS services, addiction prevention and treatment services, and primary care services, with a goal of improving the coordination of care, and improving health outcomes related to HIV, Hepatitis (optional), and substance use disorder (SUD) in the US.

Budget: NIDA expects to fund a total of \$2M in new awards in FY25 across both the R01 and R34 mechanisms. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period for the R01 is 5 years. **R34** Direct costs are limited to \$450,000 over the 3-year R34 project period, with no more than \$225,000 in direct costs allowed in any single year.

Research Development and Support Division (RDSD) & Grants Management Office (GMO)
Faculty of Medicine and Health Sciences
009 Kth Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krotoa Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105